Navigation Links
New tuberculosis drug trial begins in South Africa

Case Western Reserve University School of Medicine and AstraZeneca, a global biopharmaceutical company, today announced the first patient enrolled in a Phase 2a trial to assess the effectiveness of AZD5847, a new test drug for patients with tuberculosis (TB), including patients with HIV co-infection.

The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. It is being conducted by the NIAID-supported Tuberculosis Research Unit of Case Western University School of Medicine of Cleveland, Ohio, and is taking place in Cape Town, South Africa with TASK Applied Science, a South African clinical research group that specializes in TB trials.

TB, which causes 1.4 million deaths per year, is the leading infectious cause of death among people with HIV/AIDS . The emergence of drug-resistant TB and the lack of new drugs to fight the disease effectively are major challenges to controlling this serious global public health concern.

"New medications are greatly needed to improve and shorten the treatment of TB in high-burden countries," says John L. Johnson, MD, professor of medicine in the Division of Infectious Diseases and HIV Medicine at Case Western Reserve School of Medicine and staff physician at University Hospitals Case Medicine Center. "This trial is the first step in testing this new potential drug in humans with active TB."

Johnson is an internationally-renowned investigator with the Tuberculosis Research Unit at Case Western Reserve, an inter-disciplinary, inter-national consortium of investigators and institutions with expertise in epidemiology, microbiology, immunity, prevention and treatment of TB. Supported by the NIH, the Tuberculosis Research Unit is the only NIH-funded research unit in the US focused on human TB.

AZD5847 has been developed by AstraZeneca and belongs to a class of antibiotics that are active against Gram-positive bacteria and mycobacteria; they work by stopping the creation of proteins that are essential to bacteria's survival. AZD5847 is active in culture against a broad array of drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis, which causes TB.

"AZD5847 is one part of AstraZeneca's ongoing commitment to conducting research and collaborating across industry, academia, and government to develop novel treatments for TB and help stop the spread of the disease," said Manos Perros, head of the AstraZeneca Infection Innovative Medicines Unit. "AstraZeneca's intent is to work with partners to test the contribution of AZD5847 in Phase 2b trials as part of one or more next-generation combination therapies."

Combating TB is one of the United Nations' Millennium Development goals . The most recent TB drugs were introduced in the 1960s. Since then, some strains have developed resistance to those medications. Drug-resistant TB requires up to two years of treatment with more expensive second-line drugs that have more side effects. Many patients with drug-resistant TB go untreated in endemic countries due to a lack of medical resources. The World Health Organization estimates that 220,000 to 400,000 multi-drug resistant TB cases occurred among TB cases in 2011. About 60 percent of these cases were reported in Brazil, China, India, the Russian Federation and South Africa.


Contact: Jessica Studeny
Case Western Reserve University

Related biology news :

1. Biosignatures distinguish between tuberculosis and sarcoidosis
2. Targeting tuberculosis hotspots could have widespread benefit
3. MIT-designed cooler preserves tuberculosis drugs, records doses
4. Research on improvements in diagnosing and treating tuberculosis
5. Millions of diabetics could die of tuberculosis
6. New approach of resistant tuberculosis
7. Iowa State, Ames Lab researchers study the structure of drug resistance in tuberculosis
8. High doses of Vitamin D help tuberculosis patients recover more quickly
9. Scientists reveal how natural antibiotic kills tuberculosis bacterium
10. Notre Dame research could provide new insights into tuberculosis and other diseases
11. Missing link discovered in the defence mechanism of the tuberculosis pathogen
Post Your Comments:
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer ... what they believe could be a new and helpful biomarker for malignant pleural ... Click here to read it now. , Biomarkers are components in the ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology: